Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials

IMPORTANCE: Alzheimer disease (AD) is a neurodegenerative disorder characterized by cognitive deterioration and impaired activities of daily living. Current treatments provide only minor symptomatic improvements with limited benefit duration. Lanabecestat, a brain-permeable inhibitor of human beta-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wessels, Alette M., Tariot, Pierre N., Zimmer, Jennifer A., Selzler, Katherine J., Bragg, Sonja M., Andersen, Scott W., Landry, John, Krull, James H., Downing, AnnCatherine M., Willis, Brian A., Shcherbinin, Sergey, Mullen, Jamie, Barker, Peter, Schumi, Jennifer, Shering, Craig, Matthews, Brandy R., Stern, Robert A., Vellas, Bruno, Cohen, Sharon, MacSweeney, Emer, Boada, Mercè, Sims, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902191/
https://www.ncbi.nlm.nih.gov/pubmed/31764959
http://dx.doi.org/10.1001/jamaneurol.2019.3988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902191/
https://www.ncbi.nlm.nih.gov/pubmed/31764959
http://dx.doi.org/10.1001/jamaneurol.2019.3988

Ejemplares similares